• Explore /
  • Poster
  • / Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

Abstract Poster

Authors

null

Vikas Gupta

Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

Vikas Gupta , Srdan Verstovsek , Ruben A. Mesa , Jason R. Gotlib , John F. DiPersio , John V. Catalano , Michael W.N. Deininger , Carole Brennan Miller , Richard T. Silver , Moshe Talpaz , Elliott F. Winton , Jimmie Huling Harvey Jr., Murat O. Arcasoy , Elizabeth O. Hexner , Roger M. Lyons , Ronald Paquette , Azra Raza , Deanna Kornacki , Kang Sun , Hagop M. Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT00952289

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7012)

DOI

10.1200/JCO.2016.34.15_suppl.7012

Abstract #

7012

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Jan Philipp Bewersdorf

Poster

2014 ASCO Annual Meeting

A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.

A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.

First Author: Florian Heidel

First Author: Lucia Masarova

First Author: Aaron Thomas Gerds